MetaVia Inc. Price & Performance (MTVA)

MetaVia's stock surged in extended trading after its experimental obesity therapy, DA-1726, delivered a 6.3% reduction in body weight over 26 days in a Phase 1 trial. The results, which exceeded expectations for early-stage studies, have drawn attention to MetaVia's growing presence in the cardiometabolic market.12

SHF stock jumped over 73% in after-hours trading, reflecting renewed optimism among investors. The uptick follows a week of increasing media coverage and online attention, signaling a potential shift in sentiment for the company after a period of relative quiet in the market.3

The global market for ANGPTL3 inhibitors is projected to experience substantial growth over the next decade. Rising demand for innovative lipid-lowering treatments and ongoing advancements in clinical research are driving expectations for accelerated market expansion across major regions.1